Static List Review – June 2016
NICE Technology Appraisal Guidance No. 47; Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
As the appraisal has been on the static list for more than 5 years, NICE has been gathering intelligence to ascertain whether there is any new evidence available relevant to this appraisal and whether this should be considered through the full review proposal process.
We have concluded that there has been no change in the evidence base that is likely to lead to a change in the existing recommendations.
As a result, we have decided that TA47 should remain on the static list and no further action is required at this time.
This page was last updated: 20 June 2016